Treatment of complement-associated disorders

Details Treatment of complement-associated disorders Treatment of complement-associated disorders

2011-08-30

2011-08-30

Wen, Sharon (Department: 1644)

Drug, bio-affecting and body treating compositions

Immunoglobulin, antiserum, antibody, or antibody fragment,...

Monoclonal antibody or fragment thereof

C424S130100

Reexamination Certificate

active

08007798

ABSTRACT:
The present invention concerns a recently discovered macrophage specific receptor, CRIg, and its use in the prevention and treatment of complement-associated disorders, including complement-associated eye conditions, such as age-related macular degeneration (AMD) and choroidal neovascularization (CNV).

REFERENCES:
patent: 4579827 (1986-04-01), Sakamoto et al.
patent: 5650295 (1997-07-01), Li et al.
patent: 6022708 (2000-02-01), de Sauvage et al.
patent: 6410708 (2002-06-01), Ashkenazi et al.
patent: 6472520 (2002-10-01), Fisher
patent: 6569992 (2003-05-01), LaFleur et al.
patent: 6642353 (2003-11-01), McConnell et al.
patent: 6838554 (2005-01-01), Ashkenazi et al.
patent: 7192589 (2007-03-01), Ashkenazi et al.
patent: 7211400 (2007-05-01), Ashkenazi et al.
patent: 7282565 (2007-10-01), Goddard et al.
patent: 7419663 (2008-09-01), Ashkenazi et al.
patent: 2004/0152105 (2004-08-01), Vogt et al.
patent: 2005/0197285 (2005-09-01), Rosen et al.
patent: 2006/0233803 (2006-10-01), Ashkenazi et al.
patent: 2007/0190054 (2007-08-01), Ashkenazi et al.
patent: 0 199 141 (1986-10-01), None
patent: 317 050 (1989-05-01), None
patent: 0 616 812 (1994-09-01), None
patent: 0 616 812 (1994-09-01), None
patent: WO 90/05537 (1990-05-01), None
patent: WO 96/34943 (1996-11-01), None
patent: WO 98/24897 (1998-06-01), None
patent: WO 98/40483 (1998-09-01), None
patent: WO 98/42739 (1998-10-01), None
patent: WO 99/02561 (1999-01-01), None
patent: WO 99/27098 (1999-06-01), None
patent: WO 99/40100 (1999-08-01), None
patent: WO 99/46281 (1999-09-01), None
patent: WO 00/12703 (2000-03-01), None
patent: WO 00/29583 (2000-05-01), None
patent: WO 00/36102 (2000-06-01), None
patent: WO 00/37638 (2000-06-01), None
patent: WO 00/53749 (2000-09-01), None
patent: WO 00/53758 (2000-09-01), None
patent: WO 01/04311 (2001-01-01), None
patent: WO 01/36432 (2001-05-01), None
patent: WO 01/40466 (2001-06-01), None
patent: WO 02/00690 (2002-01-01), None
patent: WO 02/08284 (2002-01-01), None
patent: WO 02/08284 (2002-01-01), None
patent: WO 2004/022594 (2004-03-01), None
The Merck Manuals Online Medical Library, [online]. Whitehouse Station, NJ: Merck Research Laboratories, 2006-2007. [retrieved on Sep. 7, 2010]. Retrieved from the Internet: < URL: http://www.merck.com/mmpe/print/sec09/ch106/ch106b.html >. Age-Related Macular Degeneration (AMD or ARMD); pp. 1-4.
Arrate, et al., “Cloning of human junctional adhesion molecule 3 (JAM3) and its identification as the JAM2 counter-receptor”, The Journal of Biological Chemistry, vol. 276, No. 49, pp. 45826-45832, (2001).
Atwood, et al., “The babel of bioinformatics”, Science, vol. 290, pp. 471-473, (2000).
Casset, et al., “A peptide mimetic of an anti-CD4 monoclonal antibody by rational design”, BBRC, 307: 198-205, (2003).
GenBank Accession No. Q80WA3, V-set and immunoglobulin domain containg 4, VSIG4, Mar. 1, 2004, pp. 1-2.
Kahan., “Immunosuppressive therapy”, Current Opinion in Immunology, 4: 553-560, (1992).
Katschke, et al., “A novel inhibitor of the alternative pathway of complement reverses inflammation and bone destruction in experimental arthritis”, Brief Definitive Report, vol. 204, No. 6, pp. 1319-1325, (2007).
Kim, et al., “Characterization of monoclonal antibody specific to the Z39Ig protein, a member of immunoglobulin superfamily”, Immunology Letters, 99: 153-161, (2005).
Lee, et al., “Z39Ig is expressed on macrophages and may mediate inflammatory reactions in arthritis and atherosclerosis”, Journal of Leukocyte biology, vol. 80, pp. 922-928, (2006).
MacCallum, et al., “Antibody-antigen interactions: Contact analysis and binding site topography”, J. Mol. Biol., 262: 732-745, (1996).
Rudikoff, et al., “Single amino acid substitution altering antigen-binding specificity”, PNAS, vol. 79, pp. 1979-1983, (1982).
Skolnick, et al., “From genes to protein structure and function: novel applications of computational approaches in the genomic era”, Trends in Biotech, 18: 34-39, (2000).
Strausberg, et al., “Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sqeuences”, PNAS, vol. 99, No. 26, pp. 16899-16903, (2002).
Tsukita, et al., “Multifunctional strands in tight junctions”, Nature Reviews, vol. 2, pp. 285-293, (2001).
Walker, et al., “Z39Ig is co-expressed with activation macrophage genes”, Biochimica et Biophysica Acta, 1574: 387-390, (2002).
Wu, et al., “Humanization of a murine monoclonal antibody by simultaneous optimization of framework and CRD residues”, JMB, 294: 151-162, (1999).
Alderson, et al., “Molecular and biological characterization of human 4-1BB and its ligand”, European Journal of Immunology, 24(9): 2219-2227, (1994).
Altchul, et al., “Local alignment statistics”, Methods in Enzymology, 266: 460-480, (1996).
Auffray, et al., “H. sapienspartial cDNA sequence; clone c-Oxd10 partial cDNA sequence; transcribed sequence fragment”, (Database EMBL-EMEST16 Accession No. F02373) (1995).
Barsoum, et al., “Effect of microencapsulated ampicillin on cell mediated immune responses in mice”, J. Antimicrob. Chemother., , 40(5): 721-724, (1997).
Bork, et al., Trends in Genetics, 12: 425-427, (1996).
Bork, Genome Research, 10: 398-400, (2000).
Bowie, et al., Science, 247: 1306-1310, (1990).
Boyum, et al., “A one stage procedure for isolation of granulocytes and lympocytes form human blood”, Norweigan defense establishment, Div. of toxicology, pp. 51-76.
Brenner, Trends in Genetics, 15: 132-133, (1999).
Campo, et al., “Zinc inhibits the mixed lymphocyte culture”, Biology Trace elementary Res., 79(1): 15-22, (2001).
Chambers, et al., “Co-stimulation in T cell responses”, Current Opinion in Immunology, 9(3): 396-404, (1997).
Coligan, et al., “Isolation of mouse mononuclear cells”, Current Protocols in Immunology, vol. 1, unit 3.1.2, (1993).
De Smet, et al., “The activation of human gene MAGE-1 in tumor cells is correlated with genome-wide demethylation”, PNAS, 93(14): 7149-7153, (1996).
Doerks, et al., Trends in Genetics, 14: 248-250, (1998).
Finn, et al., “Introduction: Third keystone symposium on cellular immunology and the immunotherapy of cancer”, Journal of Immunotherapy, 21(2): 114-118, (1998).
GBTRANS Database Accession No. AJ132502, “HSA132502—1Z39Ig protein—Homo sapiens” (blast results) (Direct Submission Jan. 25, 1999).
GBTRANS Database Accession No. AL034397, “HS159A1—1 dA159A1.1 (novel protein)—Homo sapiens” (blast results) (Direct Submission Dec. 4, 1998).
GBTRANS Database Accession No. AL136649, “HSM801619—1 hypothetical protein” (blast results) (Direct Submission Jan. 18, 2000).
GBTRANS Database Accession No. AY016009, (blast results) (Direct Submission Dec. 4, 2000).
GBTRANS Database, Accession No. AF172398 (blast results) (Direct Submission Feb. 26, 2001).
GBTRANS Database, Accession No. AF191495 (blast results) (Direct Submission Oct. 1, 1999).
GenBank Accession No. G15647, human STS SHGC-11352, available Jan. 4, 1996.
GENESEQ Patent Database Accession No. P—B19396, (blast results) (Direct Submission Oct. 19, 2000).
GENESEQ Patent Database Accession No. P—B24047, (blast results) (Direct Submission Sep. 14, 2000).
GENESEQ Patent Database Accession No. P—B24401, (blast results) (Direct Submission Jun. 8, 2000).
GENESEQ Patent Database Accession No. P—B24405, (blast results) (Direct Submission Jun. 8, 2000).
GENESEQ Patent Database Accession No. P—B33421, (blast results) (Direct Submission Sep. 14, 2000).
GENESEQ Patent Database Accession No. P—B33429, (blast results) (Direct Submission Sep. 14, 2000).
GENESEQ Patent Database Accession No. P—B44247, (blast results) (Direct Submission Sep. 14, 2000).
GENESEQ Patent Database Accession No. P—B53081, (blast re

Affiliated with

Also associated with

Rating

Treatment of complement-associated disorders does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Treatment of complement-associated disorders, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of complement-associated disorders will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2641889